主要目的：以持证商为Les Laboratoires Servier的培哚普利氨氯地平片（Ⅰ）（商品名：COVERAM，规格：每片含精氨酸培哚普利10mg和苯磺酸氨氯地平（以氨氯地平计）10mg）为参比制剂，以南京海纳制药有限公司研发的培哚普利氨氯地平片（Ⅰ）（每片含精氨酸培哚普利10mg和苯磺酸氨氯地平（以氨氯地平计）10mg）为受试制剂，评价两种制剂在中国健康受试者中空腹和餐后状态下的生物等效性。次要目的：观察受试制剂和参比制剂在中国健康受试者中的安全性。

开始日期2024-09-05

申办/合作机构

南京海纳制药有限公司

CTR20242729 / CompletedN/A

培哚普利氨氯地平片（Ⅲ）在中国成年健康受试者中的一项随机、开放、空腹和餐后单次给药、两制剂、两序列、两周期交叉的生物等效性研究

考察空腹/餐后单次口服受试制剂培哚普利氨氯地平片（Ⅲ）（规格：每片含精氨酸培哚普利10 mg和苯磺酸氨氯地平（以氨氯地平计）5 mg，安徽佳和药业有限公司生产）与参比制剂培哚普利氨氯地平片（Ⅲ）（商品名：Coveram®，规格：每片含精氨酸培哚普利10 mg和苯磺酸氨氯地平（以氨氯地平计）5 mg，Servier (Ireland) Industries Ltd生产），在中国成年健康人体的相对生物利用度，分析两种制剂的药代动力学参数，评价两制剂的生物等效性。次要研究目的：评价空腹/餐后单次口服受试制剂和参比制剂在中国成年健康受试者中的安全性。

开始日期2024-08-20

申办/合作机构

安徽佳和药业有限公司初创企业

CTR20242507 / CompletedN/A

培哚普利氨氯地平片（Ⅲ）在中国成年健康受试者中的一项随机、开放、空腹和餐后单次给药、两制剂、两序列、两周期交叉的生物等效性研究。

主要研究目的：考察空腹/餐后单次口服受试制剂培哚普利氨氯地平片（Ⅲ）（规格：每片含精氨酸培哚普利10 mg和苯磺酸氨氯地平（以氨氯地平计）5 mg，海南皇隆制药股份有限公司生产）与参比制剂培哚普利氨氯地平片（Ⅲ）（商品名：Coveram®，规格：每片含精氨酸培哚普利10 mg和苯磺酸氨氯地平（以氨氯地平计）5 mg，Servier (Ireland) Industries Ltd生产），在中国成年健康人体的相对生物利用度，分析两种制剂的药代动力学参数，评价两制剂的生物等效性。次要研究目的：评价空腹/餐后单次口服受试制剂和参比制剂在中国成年健康受试者中的安全性。

开始日期2024-07-22

申办/合作机构

海南皇隆制药股份有限公司

100 项与苯磺酸氨氯地平/精氨酸培哚普利相关的临床结果

登录后查看更多信息

100 项与苯磺酸氨氯地平/精氨酸培哚普利相关的转化医学

登录后查看更多信息

100 项与苯磺酸氨氯地平/精氨酸培哚普利相关的专利（医药）

登录后查看更多信息

983

项与苯磺酸氨氯地平/精氨酸培哚普利相关的文献（医药）

2024-12-31·Journal of the International Society of Sports Nutrition

The effect of probiotics and casein supplementation on aerobic capacity parameters of male soccer players

Article

作者: Niknam, Alireza ; Daryanoosh, Farhad ; Koureshfard, Negar ; Rezaei, Rasoul ; Qashqaei, Ali ; Sadeghi, Reza ; Imanian, Babak ; Hemmatinafar, Mohammad

BACKGROUND:

In the realm of sports science, nutrition is a well-established pillar for athletes' training, performance, and post-workout recovery. However, the role of gut microbiota, often overlooked, is a novel and intriguing aspect that can significantly impact athletic performance. With this in mind, our study ventures into uncharted territory, investigating the effect of probiotic and casein supplementation on the aerobic capacity of male soccer players.

METHOD:

A double-blinded and placebo-controlled study was conducted with 44 male soccer players (Age: 22.81 ± 2.76 yr, Height: 177.90 ± 6.75 cm, Weight: 67.42 ± 8.44 kg). The participants were subjected to the Bruce test in the beginning; then, they were randomly divided into four groups, each consisting of 11 people: probiotics (PRO), casein (CAS), probiotics with casein (PRO+CAS), and placebo (PLA). PRO group was given one probiotic capsule (containing strains of Lactiplantibacillus plantarum BP06, Lacticaseibacillus casei BP07, Lactobacillus acidophilus BA05, Lactobacillus delbrueckii BD08 bulgaricus, Bifidobacterium infantis BI04, Bifidobacterium longum BL03, Bifidobacterium breve BB02 and Streptococcus salivarius thermophilus BT01, with a total dose of 4.5 × 10¹¹ CFU) during dinner, while the CAS group consumed 20 grams of casein powder 45 minutes before bed. The PRO+CAS group was given one probiotic capsule during dinner and 20 grams of casein powder 45 minutes before bed. The participants in the PLA group were given one red capsule (containing 5 grams of starch) during dinner. All participants were instructed to take the supplements only on training days, three times a week for four weeks. The maximal oxygen consumption (VO_2max), Ventilatory Threshold (VT), Time-to-exhaustion (TTE), Respiratory Compensation Point (RCP), Isocapnic area Time (Time-IC), Isocapnic area oxygen consumption (VO₂-IC), and Hypocapnic Hyperventilation area Time (Time-HHV), after the Bruce test were Measured. All data were analyzed using SPSS Windows software, mixed repeated measure ANOVA, and Bonferroni post hoc test at p < 0.05 level.

RESULTS:

The current study's findings illustrated that, after the intervention, TTE (p = 0.01) and RCP (p = 0.01) were significantly improved in PRO+CAS compared to the PLA group. No significant difference was observed between PRO and PLA (p = 0.52), PRO and CAS (p = 0.999), PRO and PRO+CAS (p = 0.9), CAS and PLA (p = 0.65), CAS and PRO+CAS (p = 0.73) in TTE. In addition, no significant difference was observed between PRO and CAS (p = 0.999), PRO and PLA (p = 0.40), PRO and PRO+CAS (p = 0.999), CAS and PLA (p = 0.263), CAS and PRO+CAS (p = 0.999) in RCP. Time-HHV was significantly higher in PRO+CAS (p = 0.000) and CAS (p = 0.047) compared to the PLA group. However, no significant difference was observed in the Time-HHV between PRO and CAS (p = 0.999), PRO and PRO+CAS (p = 0.25), PRO and PLA (p = 0.12), and CAS and PRO+CAS (p = 0.57). Additionally, all the groups had no significant differences in VO_2max, VT1, VO₂-IC and Time-IC.

CONCLUSION:

The findings showed that consuming probiotics and casein could relatively improve the aerobic capacity of male soccer players. Nevertheless, simultaneous consumption of probiotics and casein had a more pronounced effect on aerobic capacity indicators, especially TTE and Time-HHV.

2024-12-31·Gut microbes

Sialic acid-based probiotic intervention in lactating mothers improves the neonatal gut microbiota and immune responses by regulating sialylated milk oligosaccharide synthesis via the gut–breast axis

Article

作者: Yu, Da ; Ze, Xiaolei ; Li, Zhi ; Ning, Xixi ; Zhang, Xuguang ; Deng, Yanjie ; Wang, Yushuang ; Liu, Yujia ; Li, Liang ; Rui, Binqi ; Li, Ming ; Liu, Yinhui ; Xi, Yu ; Li, Wenzhe ; Lei, Zengjie ; Yan, Jingyu ; Yuan, Jieli

Human milk oligosaccharides (HMOs) are vital milk carbohydrates that help promote the microbiota-dependent growth and immunity of infants. Sialic acid (SA) is a crucial component of sialylated milk oligosaccharides (S-MOs); however, the effects of SA supplementation in lactating mothers on S-MO biosynthesis and their breastfed infants are unknown. Probiotic intervention during pregnancy or lactation demonstrates promise for modulating the milk glycobiome. Here, we evaluated whether SA and a probiotic (Pro) mixture could increase S-MO synthesis in lactating mothers and promote the microbiota development of their breastfed neonates. The results showed that SA+Pro intervention modulated the gut microbiota and 6'-SL contents in milk of maternal rats more than the SA intervention, which promoted Lactobacillus reuteri colonization in neonates and immune development. Deficient 6'-SL in the maternal rat milk of St6gal1 knockouts (St6gal1^-/-) disturbed intestinal microbial structures in their offspring, thereby impeding immune tolerance development. SA+Pro intervention in lactating St6gal1^± rats compromised the allergic responses of neonates by promoting 6'-SL synthesis and the neonatal gut microbiota. Our findings from human mammary epithelial cells (MCF-10A) indicated that the GPR41-PI3K-Akt-PPAR pathway helped regulate 6'-SL synthesis in mammary glands after SA+Pro intervention through the gut - breast axis. We further validated our findings using a human-cohort study, confirming that providing SA+Pro to lactating Chinese mothers increased S-MO contents in their breast milk and promoted gut Bifidobacterium spp. and Lactobacillus spp. colonization in infants, which may help enhance immune responses. Collectively, our findings may help alter the routine supplementation practices of lactating mothers to modulate milk HMOs and promote the development of early-life gut microbiota and immunity.

2024-12-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Propolis-loaded photocurable methacrylated pullulan films: Evaluation of mechanical, antibacterial, biocompatibility, wound healing and pro-angiogenic abilities

Article

作者: İdil, Neslihan ; Özkahraman, Bengi ; Torkay, Gülşah ; Akar, Remzi Okan ; Bal-Öztürk, Ayça ; Özbaş, Zehra

The ultimate goal of this study was to establish the groundwork for the development of high-mechanical pullulan based films for wound healing applications. For this purpose, pullulan (PUL) was successfully methacrylated with different methacrylic anhydride amounts and used for the fabrication of photocurable wound dressing films (PULMA). The mechanical properties of the films, evaluated by changing the methacrylation degree and polymer concentration for better mechanical performance, indicated the best results in terms of elastic modulus (2.55 ± 0.15 MPa), tensile strength (2.48 ± 0.12 MPa), and elongation at break (848 ± 111 %). Additionally, the incorporation of PRO into wound dressing films has demonstrated strong antibacterial activity against Escherichia coli and Staphylococcus aureus, and it has also improved the release profile. The obtained films have scavenging properties against 2,2-diphenyl-1-picrylhydrazyl (DPPH). The wound dressing films were not cytotoxic to NIH/3T3 cells, a fibroblast cell line, according to the cytotoxicity assay. The in vitro scratch test showed that PRO incorporated films induced cell migration, suggesting that they have the potential to close wounds and promote healing. According to the image analysis conducted following the in ovo chorioallantoic membrane (CAM) test, PRO inclusion boosted different angiogenesis parameters stemming from the films. Clear evidence has been found that PRO loaded into high mechanical performance PUL based films can be suitable for advanced wound dressing applications.

项与苯磺酸氨氯地平/精氨酸培哚普利相关的新闻（医药）

2024-02-24

·药智网

未来5年，10款重磅炸弹药物的关键专利到期

专利保护是一款药物甚至一家企业赖以持续性发展的关键武器，这一点在艾伯维的修美乐身上体现得最为明显。未来5年，将有多款重磅炸弹级药物的关键专利到期，这将为制药行业，尤其是仿制药和生物类似药开发商带来巨大的商机。以下是10款未来5年关键专利到期的重磅炸弹，它们在2023年的总销售额超过了800亿美元。表1 未来5年，关键专利到期的10款重磅炸弹药物数据来源：综合各家企业财报注意：第八个药品的销售额为Prevnar 13和Prevnar 20的共同销售额。01Keytruda有效成分：Pembrolizumab开发商：默沙东适应症：三阴性乳腺癌、黑色素瘤、非小细胞肺癌、头颈鳞状细胞癌、尿路上皮癌、结肠癌或直肠癌。2023年销售：250亿美元关键专利到期：2028年Keytruda于2014年首次获得FDA批准用于治疗多种类型的癌症。自获得最初批准以来，Keytruda的获批适应症不断增加，包括了黑色素瘤、非小细胞肺癌、头颈癌等。2023年，Keytruda占默沙东药品销售额的40%，这款新药王也成为默沙东最成功的产品。Keytruda预计将于2028年失去专利保护，为生物类似药竞争打开大门。Keytruda的销售额预计将在2029年降至274亿美元，比预计的2028年337亿美元销售额下降19%。为了抵消收入的大幅下降，默沙东正在准备通过建立早期资产管道来加强其免疫治疗产品组合。除此之外，默沙东于2024年初达成最终协议，以6.8亿美元收购Harpoon Therapeutics，这将进一步推进其肿瘤学产品组合。02Eliquis有效成分：Apixaban开发商：百时美施贵宝和辉瑞适应症：降低心律失常患者中风或血栓的风险关键专利到期时间：2027年至2029年2023年销售额：122亿美元Eliquis是一种用于预防成人血栓的药物。Eliquis最初于2011年5月在欧盟获得批准，并于2012年12月在美国获得批准，已成为深静脉血栓（Deep Vein Thrombosis）和肺栓塞（Pulmonary Embolism）最有效的治疗选择之一。Eliquis是心血管疾病领域2023年销售额排名榜第一的药物（122亿美元），远高于第二位的诺华的Entresto（58亿美元）。预计Eliquis将一直保持这一桂冠至2028年。随着Eliquis的专利将在未来几年内到期，百时美施贵宝和辉瑞公司的Eliquis的仿制药已经获得FDA的临时批准。由于和解外加一项关键诉讼，这两家制药巨头至少能在2027年之前守住Eliquis的市场阵地。目前尚不清楚Eliquis仿制药具体何时能够进入市场，但应该不会早于2027年。FDA授予了Eliquis儿科使用的延申，这将为其延长六个月的市场独占期。03Eylea有效成分：Aflibercept开发商：再生元、拜耳适应症：湿性年龄相关性黄斑变性等眼部疾病关键专利到期时间：2025年至2026年2023年销售额：58.86亿美元（美国）Eylea于2011年获得FDA批准用于治疗湿性年龄相关性黄斑变性、糖尿病性视网膜病变以及糖尿病性和非糖尿病性黄斑水肿。2023年，Eylea特许经营在美国的销售额达到59亿美元。专家预计Eylea的专利将于2025年或2026年结束，尽管Regeneron向投资人宣称，他们的市场独占期可能会更长。与此同时，Sandoz和Viatris等大型制药公司已经瞄准了市场份额，积极开发生物类似药并抢占市场。04Opdivo有效成分：nivolumab公司：百时美施贵宝适应症：多种癌症关键专利到期：2028年2023年销售额：90.09亿美元百时美施贵宝的Opdivo（nivolumab）是一种免疫疗法，用于治疗多种不同的癌症，是当今药王Keytruda的直接竞争对手。虽然销售额上不及Keytuda的一半，但也在2023年实现了90.09亿的销售业绩，称得上是巨型重磅炸弹。得益于一些新的适应症的获批，Opdivo在过去几年中出现了令人印象深刻的增长，销售额2023年增长9%，预计到2026年销售额将达到117.5亿美元。但BMS将在2028年失去Opdivo的美国市场独占权。总部位于悉尼的NeuClone Pharmaceuticals、瑞典公司Xbrane Biopharma和中国绿叶制药已经在致力于开发nivolumab生物类似药。未来几年内有好几款巨型重磅炸弹药物的专利到期都涉及BMS，除了Opdivo之外，癌症药物Revlimid和辉瑞合作的血液稀释剂Eliquis的独家经营权都将面临丧失。BMS目前正在努力推出六种新药，这些药物合计可能贡献超过150亿美元的销售额。05Ibrance有效成分：Palbociclib适应症：HR阳性和HER2阴性乳腺癌开发商：辉瑞关键专利到期：2027年2023年销售额：47.53亿美元尽管辉瑞预计他们的抗肿瘤药物Ibrance在2027年之前不会失去美国市场独占权，但这并不能阻止仿制药公司开发各自的Palbociclib仿制药。2019年已有多家仿制药制造商通知辉瑞，他们已向FDA递交了Ibrance仿制药的申请。尽管他们的理由是认为Ibrance的两项关键专利无效，但辉瑞还是成功获得了4年延期，直至2027年。实际上，Ibrance的销售额在2023年已经出现了下降，从一年前的51.2亿美元下降到了47.53亿美元，这主要是由于竞争压力和某些国际市场的临床试验采购减少导致全球需求下降。由于Ibrance的未来充满不确定性，过去几年，辉瑞一直在努力增强其肿瘤产品组合，包括收购Array BioPharma、Seagen和Trillium Therapeutics的交易。06Xarelto有效成分：Rivaroxaban适应症：血栓公司：拜耳/强生关键专利到期：2026年2023年销售额：23.65亿美元Xarelto（Rivaroxaban）于2007年获得专利，并于2011年在美国批准用于医疗用途，用于治疗和预防血栓。这种抗凝剂由拜耳和强生旗下杨森制药公司联合开发，仅在美国就已被开出超过8000万次处方。2022年，它是拜耳最畅销的药品，带来了价值45.16亿欧元的收入。预计拜耳将在2026年失去Xarelto的独占权。而在美国市场，Lupin的Rivaroxaban仿制药（RLD Xarelto）已经收到了FDA的暂定批准，正在积极准备将其仿制药推向市场。随着Xarelto和Eylea两大明星产品即将到期，拜耳一直在寻找新的增长机会，并专注于进一步扩大其在细胞和基因治疗领域的开发组合。07Trulicity有效成分：dulaglutide开发商：礼来适应症：2型糖尿病关键专利到期：2027年2023年销售额：70亿美元Trulicity为注射剂型，用于治疗成人和10岁以上儿童的2型糖尿病。Trulicity于2014年获得批准，其有效成分daluglutide的专利保护将于2027年到期，届时将为仿制药商是让开道路。Trulicity在2023年成为全球第17位最畅销药物。在推出了tirzepatide灌装的Mounjaro和Zepbound之后，trulicity的逐渐式微带给礼来的冲击将会被顺利化解。08Prevnar 13开发商：辉瑞适应症：肺炎链球菌菌株引起的感染关键专利到期：2026年2023年销售额：64亿美元（Prevnar 13/20的共同销售额）辉瑞公司的Prevnar 13是一种疫苗，用于预防13种肺炎链球菌菌株引起的感染，这些细菌可导致肺炎、脑膜炎和其他严重疾病。Prevnar 13接种于2009年底在欧洲首次用于婴儿，随后于2010年2月获得FDA批准。2015年，美国联邦政府推荐该疫苗用于65岁以上的人群，这为辉瑞带来了巨大的利润。Prevnar 13的专利预计将于2026年到期。为了弥补Prevnar 13专利到期导致的损失，辉瑞在研发方面投入巨资，并在2023年获得了7项FDA批准，并通过2023年12月收购Seagen Inc来加强其肿瘤产品组合。09Ocrevus有效成分：Ocrelizumab开发商：罗氏适应症：复发性或早期原发性进行性多发性硬化症关键专利到期：2028年2023年销售额：63.81亿瑞士法郎（72.46亿美元）罗氏的复发性或早期原发性进行性多发性硬化症药物Ocrevus（Ocrelizumab）是他们2023年销售量第二的资产，收获了63.81亿瑞士法郎（72.46亿美元）的销售额。Ocrevus在美国专利预计将于2029年到期，德国、法国、西班牙、英国和意大利的专利也将于2028年到期。许多生命科学公司都在竞相开发Ocrelizumab的生物类似药，其中包括韩国生物制药公司Celltrion，该公司于2023年宣布已获得3期批准。罗氏仍然专注于内部开发，最近宣布其新的乳腺癌治疗药物inavolisib取得了非常有希望的结果。他们还在项目和企业并购方面加大投入，强化他们在炎症性肠病和心脏代谢疾病等领域的投资组合。10Prolia/Xgevav有效成分：Denosumab开发商：安进适应症：继发性骨癌关键专利到期：2025年至2026年2023年销售额：40.48亿美元（Prolia），21.11亿美元（Xgeva）Prolia/Xgeva(Denosumab)于2010年获得FDA批准，是继发性骨癌的治疗药物。在欧洲的一些地区，Prolia/Xgeva已经失去了专利保护，其在美国、法国、意大利、西班牙和英国等主要市场的专利保护将于2025年至2026年间到期。Ref.1.Burke,H.Top 10 drugs with patents due to expire in the next five years.Proclinical.16.02.2024.2.Elmhirst,E.Eliquis:the cardio drug that cannot be beat.3.Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023.BMS Press Release.02.02.2024.4.Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance.Pfizer Press Release.30.01.2024.5.Lupin Receives Tentative Approval from U.S.FDA for Rivaroxaban Tablets USP.Lupin Press Release.23.01.2024.6.Gardner,J.Lilly sales surge on obesity,diabetes drug demand.Biopharma Dive.06.02.2024.7.Investor Update.Ad hoc announcement pursuant to Art.53 LR.Roche Press Release.01.02.2024.8.Amgen reports fourth quarter and full year 2023 financial results.Amgen Press Release.06.02.2024.声明：本内容仅用作医药行业信息传播，为作者独立观点，不代表药智网立场。如需转载，请务必注明文章作者和来源。对本文有异议或投诉，请联系maxuelian@yaozh.com。责任编辑 | 红色转载开白 | 马老师 18996384680（同微信）商务合作 | 王存星 19922864877（同微信）阅读原文，是受欢迎的文章哦

专利到期生物类似药财报并购

2024-02-21

·BioSpace

Discover this new generic drug in the PERINDOPRIL range

MONTREAL, Feb. 21, 2024 /CNW/ - Pharmascience Canada is proud to announce the launch of pms-PERINDOPRIL-AMLODIPINE (perindopril arginine and amlodipine), a drug indicated for the treatment of mild to moderate essential hypertension in adults aged 18 to 65 for whom combination therapy is appropriate. This oral treatment contains two medicines, perindopril arginine and amlodipine. They work together to control the blood pressure. pms-PERINDOPRIL-AMLODIPINE are available in bottles of 100 tablets and comes in the following dosage forms: 3.5 mg / 2.5 mg (this treatment is indicated for initial therapy in patients with mild to moderate essential hypertension.) 7 mg / 5 mg 14 mg / 10 mg This medication is a generic equivalent of Viacoram MD1. pms-PERINDOPRIL-AMLODIPINE tablets are available at affordable prices. « We are excited to introduce Perindopril Amlodipine to the Canadian market, as it reflects our mission to improve the health and quality of life of Canadians through innovative and high-quality products, » said Mike Dutton, Vice-President and General Manager of Pharmascience Canada. « Perindopril Amlodipine is manufactured in our Canadian facility which is another example of how we leverage our expertise and capabilities to deliver value to our customers and patients. » ABOUT PHARMASCIENCE INC. Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 50 countries. Ranked 50th among Canada's top 100 Research & Development (R&D) investors in 2022, with 40-50 million dollars invested each year, Pharmascience Inc. is among the largest drug manufacturers in Canada. Pharmascience Inc. has strong values based on the importance of investing in its employees and young people. Through various programs and initiatives, the company ensures it supports their personal development and life. In 2024, the company was awarded Great Place to Work certification for the third year running. PRVIACORAM®1 is a registered trademark owned by Servier Canada Inc. For product information, please contact Pharmascience's Medical Information Department at 1-888-550-6060. SOURCE Pharmascience Inc.

上市批准

2023-06-20

·PRNewswire

Growing Awareness of Brain Health for Senior Dogs as Cascade Animal Sciences Launches "Neuro-Pro"

ATLANTA, June 20, 2023 /PRNewswire/ -- Cascade Animal Sciences, an animal health start-up based in the United States and Australia, is proud to announce the launch of its first dietary supplement product "Neuro-Pro". Neuro-Pro is designed for middle-to-senior-aged dogs and dogs that require neurological support. It is added to their regular feed and contains a medium-chain triglyceride (MCT) formulation that acts as an alternative fuel source for the brain and has anti-inflammatory effects. Thanks to modern veterinary medicine and improved home care, dogs are living longer than ever before. However, as dogs age, they can experience a decline in cognitive function, affecting their day-to-day quality of life. This reduction in quality of life can be equally distressing for owners as it is for dogs. "Even with the growing awareness of geriatric care and neurological disorders in veterinary medicine through landmark projects like the Dog Aging Project", said Dr. Alice Edwards, Chief Veterinary Officer and a founder at Cascade "cognitive decline is still overlooked by many due to its subtle and gradual process. We hope to shine a further spotlight on this to ensure a better quality of life for dogs." Neuro-Pro's liquid formulation leverages the latest research in biochemistry and canine nutrition, containing decanoic (C10) and octanoic (C8) MCTs, which have anti-inflammatory effects on the brain and provide it with an alternative energy source, respectivel, as demonstrated in Image 1 below. . MCT-enriched diets have been shown to improve 5-out-of-6 measurements of cognitive decline in dogs within 30 days of commencement, with significant improvement across all measurements after 90 days. Furthermore, studies have demonstrated the benefits of MCTs linked to energy metabolism in dogs with epilepsy. In a 2021 study that examined the cognitive abilities of dogs with epilepsy, significant improvements in spatial working memory, problem-solving abilities, and owner trainability were observed secondary to the use of MCTs. In that regard, Cascade will also work with the veterinary industry in using MCTs as a means to support the cognitive health of dogs with epilepsy and to reduce the side of effects anti-epileptic drugs. According to Dr. Sean Hughes, a biochemist by training and Cascade's Chief Scientific Officer, "The brain is a highly energy-dependent organ that requires a constant supply of energy to function. Unfortunately, as dogs age, it is believed that their brains become less efficient at using glucose as an energy source, which can lead to a decline in cognitive function and quality of life." Dr Hughes added, "In addition to crossing the blood-brain barrier and being metabolised, the C10 fatty acids in Neuro-Pro provide neuronal anti-inflammatory effects. Neuro-Pro's formulation also contains C8 triglycerides, which, once metabolised, provide an alternative energy source for the brain in the form of ketones. This can help support overall brain health and play a role in preserving cognitive function." MCT-enriched diets in dogs and humans mimic some of the well-documented neurological and metabolic benefits of a ketogenic diet and fasting (such as those mentioned above). However, in contrast to MCT supplementation, ketogenic diets and fasting have inflexible, unsustainable, and sometimes dangerous requirements. Regarding the need for easy-to-incorporate tools that are preventative and support cognitive health in dogs, Dr. Edwards noted that "Cascade's sole focus is to provide veterinarians and dog owners with a simple way to achieve better brain health - and thereby improved quality of life. We see Neuro-Pro as a game changer for dog owners as it can be easily incorporated into a dogs' preferred diet, meaning that owners do not need to overhaul their feeding regime. We are thrilled to bring this to market and to offer a new way to support both canine neurological health and quality of life, particularly for senior dogs." About Neuro-Pro: Neuro-Pro is suitable for use in dogs of all breeds and sizes and comes in an easy-to-administer liquid formulation that is added to regular feed. It is available for sale in the USA directly from Cascade's website () and to Australia and the U.K. through international shipping. About Cascade Animal Sciences: Cascade Animal Sciences is an animal health company focused on making cognitive health in dogs more accessible, through dietary supplements such as its flagship product "Neuro-Pro". Media Contact: Tim Gibney, Cascade Animal Sciences (+614 38078 245); [email protected] SOURCE Cascade Animal Sciences

100 项与苯磺酸氨氯地平/精氨酸培哚普利相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	C09BB04	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
高血压	马来西亚	Les Laboratoires Servier SAS	2010-05-03

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
原发性高血压	临床3期	美国	Symplmed Pharmaceuticals LLC	2012-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESC2016	N/A	高血压	102	Perindopril/amlodipine combination	鹽選淵繭齋簾觸鹽窪衊(鏇衊繭齋廠構糧獵廠夢) = 夢淵蓋壓願鬱築壓鹹膚糧顧夢艱糧夢範鑰糧顧 (艱餘製醖鬱網鹽繭淵憲 )	-	2016-12-07
POTENTIAL study (ESC2016)	N/A	-	459	FDC perindopril arginine/amlodipine	築壓憲淵顧選遞構觸廠(衊願廠網壓衊觸憲積網) = 膚積鏇壓夢齋築淵鑰衊襯窪遞夢醖壓鬱淵醖願 (獵繭積積構鹹醖鑰壓繭 )	-	2016-08-28
				Free combinations of lisinopril + amlodipine	築壓憲淵顧選遞構觸廠(衊願廠網壓衊觸憲積網) = 糧鏇築遞淵窪觸觸壓衊襯窪遞夢醖壓鬱淵醖願 (獵繭積積構鹹醖鑰壓繭 )
NCT01556997 (PATH, CTgov)	临床3期	原发性高血压	837	XOMA 985 (XOMA 985)	憲網構憲簾蓋糧衊廠鏇(襯構艱選壓築鑰築觸淵) = 積衊顧膚製衊壓壓鹹簾淵鹽醖鹹淵鏇糧衊簾壓 (網製構艱壓選顧壓選觸, 鏇艱廠艱網選鹹構膚鏇 ~ 鬱壓遞鑰壓廠鏇憲鬱網) 更多	-	2015-08-25
				Amlodipine Besylate (Amlodipine Besylate (AMLb))	憲網構憲簾蓋糧衊廠鏇(襯構艱選壓築鑰築觸淵) = 憲蓋衊網觸艱構廠觸齋淵鹽醖鹹淵鏇糧衊簾壓 (網製構艱壓選顧壓選觸, 壓範廠願遞衊憲餘獵夢 ~ 糧鑰醖艱餘鑰鑰範淵鬱) 更多